Visterra Closes $30 Million Series B Financing – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek

02 October 2014

Cambridge, MA – October 2, 2014 Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, today announced that it has completed a $30 million Series B financing round. The proceeds will be used to advance the development of multiple product candidates from the company’s […]

Continue Reading

Holaira Named FierceMedicalDevices’ 2014 Fierce 15

01 October 2014

The scoop: Drug options for chronic obstructive pulmonary disease (COPD) are only modestly effective. Holaira is betting that its lung denervation device can improve COPD treatment, either as a replacement for drugs or in addition to them. COPD is characterized by persistent airflow limitation caused by progressive narrowing of the airways. This leads to shortness […]

Continue Reading